Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29th

Ticker(s): ARIA, TKPYY, PFE, NVS, RHHBY, Genentech

Who's the expert?

An oncologist or pulmonologist with experience treating patients with ALK-positive non-small cell lung cancer, and knowledge of the data surrounding Brigatinib.

Interview Questions
Q1.

Please describe your background and experience treating patients with ALK-positive NCSCLC.

Added By: pjloria
Q2.

About how many patients are you currently seeing in your practice, and how many are on an effective treatment regimen?

Added By: pjloria
Q3.

Can you discuss other approved products for the space, including Pfizer's Xalkori, Novartis' Zykadia, and Genentech's Alecensa? How many of your patients currently take these products and how would you describe their safety and efficacy?

Added By: pjloria
Q4.

How does Brigatinib compare to these current treatments in terms of safety and efficacy? Please discuss any differences in mechanism of action, safety, and efficacy between these drugs

Added By: pjloria
Q5.

What do you think of the chances of approval for Brigatinib on April 29th?

Added By: pjloria
Q6.

How much of the market share do you think Brigatinib will capture assuming it is approved? Does it have potential to be a major treatment or fit a niche need in the space?

Added By: pjloria
Q7.

How do you see the market share for these products evolving over the next couple of years? Will one of these products dominate the market?

Added By: pjloria

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.